PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300
| 应用 | 稀释度 | 推荐种属 |
|---|---|---|
| FCM | 5μl per million cells in 100μl volume | Hu |
CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, including mucosal-associated invariant T (MAIT) cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 (LLT1, also known as CLEC2D), and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.
Flow cytometric analysis of Human CD161 expression on human PBMC (human peripheral blood mononuclear cells). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD4 Antibody and either FITC Mouse IgG1, κ Isotype Control (Left panel) or SDT FITC Mouse Anti-Human CD161 Antibody (Right panel) at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
您现在的位置：